Post-pandemic recovery stocks run out of puff
The Covid-19 vaccines have been successful. Many plays on the global recovery have not done so well.


On 9 November 2020, Pfizer and BioNTech announced that their vaccine for Covid-19 was more effective than almost anybody had hoped, with more than 90% protection against the virus. The news sparked a strong rally in global stockmarkets. Many sectors such as airlines and retail that had been crushed by the closure of the global economy surged on hopes that the world would return to normal, as did broader groupings such as emerging markets and value stocks.
One year on, the Pfizer/BioNTech vaccine and others have met all reasonable expectations. The world has partially reopened, even if a lot of government policies remain clearly irrational and panicky. Yet the outcome for markets hasn’t been as expected. Some much-touted bets have turned out poorly, while some huge returns have come from stocks that were supposed to fall out of favour.
Growth is beating value
We can certainly see plenty of big winners from reopening, especially in retail and leisure. In the UK, bakery chain Greggs and transport operator FirstGroup have both gained over 100%, as has Saga, which offers tours and cruises. But the MSCI World Value index returned 29% in sterling terms over the year, compared to 26% for the MSCI World Growth – a modest difference and one that vanishes if your starting point is one day later. And in recent months, growth has come back more strongly.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Sectors such as airlines have done poorly on the whole, up 20% compared with more than 40% for technology. Some of the stay-at-home/work-from-home plays have fallen (eg, online fitness firm Peloton), but many of the tech heavyweights have kept soaring: Microsoft is up 60% and Alphabet up 70%. I’m personally relieved by both of those, because they have helped offset many of the emerging markets in my portfolio: the MSCI Emerging Markets index is up just 5% compared with 27% for the MSCI World.
There are obvious reasons for some of these disappointments. Travel restrictions continue to hold back airlines and are taking longer to remove than expected. Emerging markets have suffered from a slow vaccine roll-out, the loss of tourism and the many economic consequences of the pandemic. Some such as India, Russia and Vietnam have done well, but others such as Brazil are still suffering. Supply-chain bottlenecks, rising labour costs, and higher energy prices play a part, although many of these bring winners as well as losers: energy is up almost 60% over the year.
However, the broader lesson is that investors would rather bet on growth in these uncertain times, no matter how cheap value looks. With plenty of worries for the winter months ahead, there isn’t an obvious catalyst to change that.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Cris Sholto Heaton is an investment analyst and writer who has been contributing to MoneyWeek since 2006 and was managing editor of the magazine between 2016 and 2018. He is especially interested in international investing, believing many investors still focus too much on their home markets and that it pays to take advantage of all the opportunities the world offers. He often writes about Asian equities, international income and global asset allocation.
Cris began his career in financial services consultancy at PwC and Lane Clark & Peacock, before an abrupt change of direction into oil, gas and energy at Petroleum Economist and Platts and subsequently into investment research and writing. In addition to his articles for MoneyWeek, he also works with a number of asset managers, consultancies and financial information providers.
He holds the Chartered Financial Analyst designation and the Investment Management Certificate, as well as degrees in finance and mathematics. He has also studied acting, film-making and photography, and strongly suspects that an awareness of what makes a compelling story is just as important for understanding markets as any amount of qualifications.
-
Which investment trusts could benefit from lower interest rates?
As vehicles for long-term investments, many investment trusts were hit when interest rates rose in 2022. With interest rates expected to fall by the end of the year, could now be the time to invest in one of these unloved sectors?
-
How to protect your personal and financial data from cyber attacks
M&S and the Co-op are the latest retailers to suffer from cyber hacks but consumers also need to be vigilant
-
Unilever braces for inflation amid tariff uncertainty – what does it mean for investors?
Consumer-goods giant Unilever has made steady progress simplifying its operations. Will tariffs now cause turbulence?
-
Two ways to tap into monopoly profits from airports
Most investors can’t get their hands on airports. Here are two ways you can
-
Fat profits: should you invest in weight-loss drugs?
The latest weight-loss treatments could transform public health and the world economy. Should you invest?
-
How investors could profit from Ramsden Holdings' four-part growth strategy
Ramsdens Holdings offers a diversified set of financial and retail services and a juicy yield, says Dr Michael Tubbs
-
How to invest in the booming insurance market
The insurance sector is experiencing rapid growth after years of stagnation. Smart investors should buy in now, says Rupert Hargreaves
-
Why the 'Great Rotation' away from US assets will boost Britain
Opinion Disenchanted investors have only just begun to withdraw capital from America, says Jeremy McKeown.
-
Out of America's shadow: Why Trump's tariff chaos may be good for non-US stocks
Opinion Upending global investment and trade could benefit other countries at the expense of the US market, says Cris Sholto Heaton
-
BP's 'long, painful decline' – and why next year could be even tougher
Opinion Long-suffering shareholders in oil giant BP have been pushing for change. It won’t come soon enough, says Matthew Lynn